Regulatory PathRegulatory requirements compared

Active substance

Sulindac

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
CLINORIL TAB 200MG200 mgTablet · Oral use30 BlisterSAR 49.70NCE · PrescriptionMERCK SHARP & DOHMEWithdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
SULINDAC200MGtablet · oralWATSON LABSPrescription3 Mar 1988
SULINDAC150MGtablet · oralWATSON LABSPrescription3 Mar 1988
SULINDAC200MG; 150MGtablet · oralEPIC PHARMAPrescription25 Mar 1991
SULINDAC150MGtablet · oralSUN PHARM INDUSTRIESPrescription17 Apr 1991
SULINDAC200MGtablet · oralSUN PHARM INDUSTRIESPrescription17 Apr 1991
CLINORIL150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**tablet · oralMERCKDiscontinued27 Sep 1978
SULINDAC150MGtablet · oralCHARTWELL RXDiscontinued30 Aug 1991
SULINDAC200MGtablet · oralCHARTWELL RXDiscontinued30 Aug 1991
SULINDAC150MGtablet · oralRADIUS PHARMSDiscontinued6 Sep 1991
SULINDAC200MG; 150MGtablet · oralEPIC PHARMA LLCDiscontinued6 Sep 1991
SULINDAC200MG; 150MGtablet · oralANI PHARMSDiscontinued28 Feb 1992
SULINDAC150MGtablet · oralMYLANDiscontinued22 Jun 1993
SULINDAC200MG; 150MGtablet · oralRISINGDiscontinued22 Jun 1993

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
TEVA-SULINDAC00745588150 MGTABLET · ORALTEVA CANADA LIMITED
TEVA-SULINDAC00745596200 MGTABLET · ORALTEVA CANADA LIMITED

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACSULINDAC 150 MG TABLET$0.18906per EA23 Sep 2026
US NADACSULINDAC 200 MG TABLET$0.221per EA23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.